Ebrahim Variava
Overview
Explore the profile of Ebrahim Variava including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
2233
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meel R, Sothoane K, Variava E
Oxf Med Case Reports
. 2025 Feb;
2025(2):omae189.
PMID: 39990028
The global incidence of Cor Triatriatum ranges from 0.1% to 0.4 globally. It is a rare diagnosis, with only a few cases reported in Africa. This case report outlines the...
2.
Moosa A, Variava E, Calver A, Chita G, Sabet N, Ngwenya S, et al.
South Afr J HIV Med
. 2025 Jan;
25(1):1638.
PMID: 39822280
Background: Liver disease is the leading cause of non-AIDS-related mortality in people living with HIV (PLWH). Steatotic liver disease (SLD) is increasingly recognised as an important aetiological factor in liver...
3.
Nabeemeeah F, Sabet N, Otwombe K, Hlongwane K, Mlambo L, Moloantoa T, et al.
BMJ Open
. 2025 Jan;
14(12):e080553.
PMID: 39806691
Purpose: In the setting of an established childhood pneumococcal vaccination programme with immediate initiation and treatment of antiretroviral therapy (ART) for people living with HIV (PLWH), the risk of adult...
4.
Elf J, Lebina L, Motlhaoleng K, Chon S, Niaura R, Abrams D, et al.
AIDS
. 2024 Dec;
39(5):526-534.
PMID: 39693492
Objective: The purpose of this study was to evaluate the efficacy of combination nicotine replacement therapy (c-NRT) for smoking cessation among people with HIV (PWH) in South Africa. Design: We...
5.
Ditlhabolo K, Lion-Cachet C, Variava E
S Afr Fam Pract (2004)
. 2024 Nov;
66(1):e1-e10.
PMID: 39494661
Background: High systolic blood pressure remains a leading modifiable risk factor for cardiovascular diseases worldwide and in South Africa (SA). Information about the extent of guideline implementation and blood pressure...
6.
Moyes J, Tempia S, Walaza S, Cohen A, Treurnicht F, Hellferscee O, et al.
BMC Infect Dis
. 2024 Oct;
24(1):1128.
PMID: 39385077
Background: Identifying risk factors for respiratory syncytial virus (RSV)-associated severe acute respiratory illness (SARI) will assist with targeting vaccine interventions. Methods: Using surveillance data from South Africa (2012-2018), we compared...
7.
Chiwandire N, Walaza S, von Gottberg A, Wolter N, du Plessis M, Moosa F, et al.
Int J Epidemiol
. 2024 Sep;
53(5).
PMID: 39305220
Background: COVID-19 vaccine effectiveness (VE) studies leveraging systematic surveillance in sub-Saharan Africa are limited. We assessed the effectiveness of two vaccines (Pfizer BNT162b2 and Johnson & Johnson Ad26.COV2.S) against SARS-CoV-2-associated...
8.
Jarrett B, Shearer K, Motlhaoleng K, Chon S, Letuba G, Qomfo C, et al.
Clin Infect Dis
. 2024 Jul;
79(3):751-760.
PMID: 39036871
Background: Tuberculosis (TB) preventive therapy (TPT) reduces the risk of TB disease in people with human immunodeficiency virus (HIV), yet uptake has been suboptimal in many countries. We assessed whether...
9.
Cevik M, Thompson L, Upton C, Rolla V, Malahleha M, Mmbaga B, et al.
Lancet Infect Dis
. 2024 May;
24(9):1003-1014.
PMID: 38768617
Background: The current tuberculosis (TB) drug development pipeline is being re-populated with candidates, including nitroimidazoles such as pretomanid, that exhibit a potential to shorten TB therapy by exerting a bactericidal...
10.
Turkova A, Chan M, Kityo C, Kekitiinwa A, Musoke P, Violari A, et al.
Contemp Clin Trials
. 2024 Apr;
142:107540.
PMID: 38636725
Background: There is increasing interest in utilising two-drug regimens for HIV treatment with the goal of reducing toxicity and improve acceptability. The D3 trial evaluates the efficacy and safety of...